Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

9.080 +0.610 (+7.20%)
Streaming Delayed Price Updated: 2:55 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in Upcoming Investor Events
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
From Personalis, Inc.
Via Business Wire
Personalis (NASDAQ:PSNL) Volume Surge Can't Mask Q1 Miss as Losses Widen ↗
Via Chartmill
Personalis Inc (NASDAQ:PSNL) Reports Mixed Q4 2025 Results and Aggressive 2026 Growth Outlook ↗
Via Chartmill
News headline image
Personalis Q1 Earnings Call Highlights ↗
Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business... 
Via MarketBeat
Topics Earnings
News headline image
Personalis (PSNL) Q1 2026 Earnings Transcript ↗
Personalis (PSNL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Personalis Reports First Quarter Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce First Quarter 2026 Financial Results
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the 25th Annual Needham Virtual Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®
From Personalis, Inc.
Via Business Wire
News headline image
Lightspeed Makes a Big Bet on Self-Driving Trucks, Loading Up on 7 Million Shares of Kodiak AI (KDK) ↗
Specializing in AI-driven autonomy for commercial and defense vehicles, Kodiak AI targets clients seeking advanced navigation solutions. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
Lightspeed Management Made a Huge Bet on Navan (NAVN) With a Purchase of 49.9 Million Shares ↗
Navan delivers AI-powered travel and expense management solutions for enterprise clients in the business software sector. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Personalis (PSNL) Q4 2025 Earnings Call Transcript ↗
Personalis (PSNL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results
From Personalis, Inc.
Via Business Wire
Top movers in Tuesday's pre-market session ↗
Via Chartmill
News headline image
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test ↗
Medicare will reimburse the company’s NeXT Personal molecular residual disease (MRD) test when used to monitor patients with early to mid-stage non-small cell lung cancer (NSCLC). 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance
From Personalis, Inc.
Via Business Wire
News headline image
AIGH Capital Dumps 2.6 Million Lumen Technologies Shares In $15.6 Million Exit ↗
This telecom provider delivers fiber, cloud, and security services to businesses and consumers across U.S. and international markets. 
Via The Motley Fool
Topics Artificial Intelligence Regulatory Compliance
News headline image
AIGH Capital Dumps 1.1 Million MaxLinear (MXL) Shares ↗
This semiconductor company provides integrated RF and mixed-signal solutions for broadband, wireless, and industrial connectivity. 
Via The Motley Fool
News headline image
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
From Personalis, Inc.
Via Business Wire
News headline image
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
News headline image
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™
From Personalis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.